1. Home
  2. BLX vs ANAB Comparison

BLX vs ANAB Comparison

Compare BLX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Latinoamericano de Comercio Exterior S.A.

BLX

Banco Latinoamericano de Comercio Exterior S.A.

HOLD

Current Price

$43.11

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$43.75

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLX
ANAB
Founded
1977
2005
Country
Panama
United States
Employees
322
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
BLX
ANAB
Price
$43.11
$43.75
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$59.90
AVG Volume (30 Days)
139.8K
407.6K
Earning Date
10-28-2025
11-04-2025
Dividend Yield
5.67%
N/A
EPS Growth
9.67
N/A
EPS
6.00
N/A
Revenue
$308,426,000.00
$169,467,000.00
Revenue This Year
$18.35
$135.45
Revenue Next Year
$6.56
N/A
P/E Ratio
$7.34
N/A
Revenue Growth
10.24
196.42
52 Week Low
$31.14
$12.21
52 Week High
$48.38
$52.47

Technical Indicators

Market Signals
Indicator
BLX
ANAB
Relative Strength Index (RSI) 36.68 45.58
Support Level $43.60 $46.89
Resistance Level $44.73 $52.47
Average True Range (ATR) 0.78 2.25
MACD -0.09 -0.96
Stochastic Oscillator 2.56 16.95

Price Performance

Historical Comparison
BLX
ANAB

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: